SUPRAX

SUPRAX- cefixime tablet
Bryant Ranch Prepack

Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Suprax (cefixime) and other antibacterial drugs, Suprax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Suprax (cefixime) is a semisynthetic, cephalosporin antibiotic for oral administration. Chemically, it is (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 72 -(Z)-[O -(carboxymethyl) oxime] trihydrate.

Molecular weight = 507.50 as the trihydrate. Chemical Formula is C16 H15 N5 O7 S2 .3H2 O

The structural formula for cefixime is:

Cefixime
(click image for full-size original)

Suprax is available for oral administration as 400 mg film coated tablets and as powder for oral suspension which when reconstituted provides either 100 mg/5 mL or 200 mg/5 mL of cefixime as trihydrate.

Inactive ingredients contained in the 400 mg tablets are: dibasic calcium phosphate, hypromellose, titanium dioxide, lactose monohydrate, polyethylene glycol, triacetin, magnesium stearate, microcrystalline cellulose and pregelatinized starch.

The powder for oral suspension contains the following inactive ingredients: strawberry flavor, sodium benzoate, sucrose, colloidal silicon dioxide and xanthan gum.

CLINICAL PHARMACOLOGY

Suprax, given orally, is about 40%-50% absorbed whether administered with or without food; however, time to maximal absorption is increased approximately 0.8 hours when administered with food. A single 200 mg tablet of cefixime produces an average peak serum concentration of approximately 2 mcg/mL (range 1 to 4 mcg/mL); a single 400 mg tablet produces an average peak concentration of approximately 3.7 mcg /mL (range 1.3 to 7.7 mcg /mL). The oral suspension produces average peak concentrations approximately 25%-50% higher than the tablets, when tested in normal adult volunteers. Two hundred and 400 mg doses of oral suspension produce average peak concentrations of 3 mcg/mL (range 1 to 4.5 mcg/mL) and 4.6 mcg/mL (range 1.9 to 7.7 mcg/mL), respectively, when tested in normal adult volunteers. The area under the time versus concentration curve is greater by approximately 10%-25% with the oral suspension than with the tablet after doses of 100 to 400 mg, when tested in normal adult volunteers. This increased absorption should be taken into consideration if the oral suspension is to be substituted for the tablet. Because of the lack of bioequivalence, tablets should not be substituted for oral suspension in the treatment of otitis media. (See DOSAGE AND ADMINISTRATION). Cross-over studies of tablet versus suspension have not been performed in children.

Peak serum concentrations occur between 2 and 6 hours following oral administration of a single 200 mg tablet, a single 400 mg tablet or 400 mg of cefixime suspension. Peak serum concentrations occur between 2 and 5 hours following a single administration of 200 mg of suspension.

TABLE
Serum Levels of Cefixime after Administration of Tablets ( mcg / mL )
DOSE 1h 2h 4h 6h 8h 12h 24h
100 mg 0.3 0.8 1 0.7 0.4 0.2 0.02
200 mg 0.7 1.4 2 1.5 1 0.4 0.03
400 mg 1.2 2.5 3.5 2.7 1.7 0.6 0.04
Serum Levels of Cefixime after Administration of Oral Suspension ( mcg / mL )
DOSE 1h 2h 4h 6h 8h 12h 24h
100 mg 0.7 1.1 1.3 0.9 0.6 0.2 0.02
200 mg 1.2 2.1 2.8 2 1.3 0.5 0.07
400 mg 1.8 3.3 4.4 3.3 2.2 0.8 0.07

Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours. In animal studies, it was noted that cefixime is also excreted in the bile in excess of 10% of the administered dose. Serum protein binding is concentration independent with a bound fraction of approximately 65%. In a multiple dose study conducted with a research formulation which is less bioavailable than the tablet or suspension, there was little accumulation of drug in serum or urine after dosing for 14 days. The serum half-life of cefixime in healthy subjects is independent of dosage form and averages 3-4 hours but may range up to 9 hours in some normal volunteers. Average AUCs at steady state in elderly patients are approximately 40% higher than average AUCs in other healthy adults.

In subjects with moderate impairment of renal function (20 to 40 mL/min creatinine clearance), the average serum half-life of cefixime is prolonged to 6.4 hours. In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours. The drug is not cleared significantly from the blood by hemodialysis or peritoneal dialysis. However, a study indicated that with doses of 400 mg, patients undergoing hemodialysis have similar blood profiles as subjects with creatinine clearances of 21-60 mL/min. There is no evidence of metabolism of cefixime in vivo.

Adequate data on CSF levels of cefixime are not available.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.